{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.70","value":"-3.63"},{"groupId":"OG001","spread":"24.51","value":"-5.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.50","value":"-6.36"},{"groupId":"OG001","spread":"25.68","value":"-8.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"178"}],"units":"Participants"}],"title":"Cycle 3 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.70","value":"-7.48"},{"groupId":"OG001","spread":"25.08","value":"-6.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"title":"Cycle 4 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.88","value":"-6.02"},{"groupId":"OG001","spread":"26.01","value":"-8.64"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"Cycle 5 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.51","value":"-6.96"},{"groupId":"OG001","spread":"26.31","value":"-8.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"title":"Cycle 6 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.42","value":"-6.83"},{"groupId":"OG001","spread":"28.44","value":"-9.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"title":"Cycle 7 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.59","value":"-7.02"},{"groupId":"OG001","spread":"25.35","value":"-4.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"title":"Cycle 8 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.04","value":"-8.46"},{"groupId":"OG001","spread":"25.49","value":"-4.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Cycle 9 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.05","value":"-4.55"},{"groupId":"OG001","spread":"26.11","value":"-6.64"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"title":"Cycle 10 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.88","value":"-4.82"},{"groupId":"OG001","spread":"25.04","value":"-5.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Cycle 11 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.81","value":"-4.67"},{"groupId":"OG001","spread":"24.63","value":"-5.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"title":"Cycle 12 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.23","value":"-3.07"},{"groupId":"OG001","spread":"25.90","value":"-4.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Cycle 13 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.25","value":"-4.21"},{"groupId":"OG001","spread":"25.99","value":"-2.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"title":"Cycle 14 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.39","value":"-2.08"},{"groupId":"OG001","spread":"25.50","value":"-3.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"Cycle 15 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.87","value":"-3.53"},{"groupId":"OG001","spread":"23.71","value":"-3.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"93"}],"units":"Participants"}],"title":"Cycle 16 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.00","value":"-0.84"},{"groupId":"OG001","spread":"26.68","value":"-0.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"title":"Cycle 17 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.96","value":"-0.98"},{"groupId":"OG001","spread":"25.00","value":"-2.62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cycle 18 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.22","value":"-1.08"},{"groupId":"OG001","spread":"26.16","value":"-2.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"title":"Cycle 19 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.68","value":"-1.89"},{"groupId":"OG001","spread":"31.91","value":"-6.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Cycle 20 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.84","value":"0.65"},{"groupId":"OG001","spread":"30.64","value":"-10.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"title":"Cycle 21 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.23","value":"-3.62"},{"groupId":"OG001","spread":"33.92","value":"-4.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"Cycle 22 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.28","value":"3.24"},{"groupId":"OG001","spread":"35.88","value":"-4.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Cycle 23 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.64","value":"1.32"},{"groupId":"OG001","spread":"34.37","value":"-6.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Cycle 24 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.99","value":"0.54"},{"groupId":"OG001","spread":"30.72","value":"-5.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Cycle 25 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.82","value":"2.78"},{"groupId":"OG001","spread":"34.27","value":"-11.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Cycle 26 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.85","value":"-0.83"},{"groupId":"OG001","spread":"31.80","value":"-2.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 27 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.38","value":"4.44"},{"groupId":"OG001","spread":"28.38","value":"-11.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 28 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.60","value":"9.52"},{"groupId":"OG001","spread":"28.38","value":"-11.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 29 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.13","value":"-8.33"},{"groupId":"OG001","spread":"20.25","value":"-14.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Cycle 30 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.53","value":"3.56"},{"groupId":"OG001","spread":"23.31","value":"4.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \\[5 items\\], role \\[2 items\\], emotional \\[4 items\\], cognitive \\[2 items\\], social \\[2 items\\]), symptom scales (fatigue \\[3 items\\], nausea \\& vomiting \\[2 items\\], pain \\[2 items\\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized population. Only those participants with data collected at specified timepoints are reported.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)","title":"Change From Baseline in EORTC QLQ-C30: Pain","type":"SECONDARY","unitOfMeasure":"score on a scale"}